Immune system protein
POPULARITY
Categories
123 episodes with antibodies
75 episodes with antibodies
42 episodes with antibodies
26 episodes with antibodies
23 episodes with antibodies
41 episodes with antibodies
39 episodes with antibodies
41 episodes with antibodies
39 episodes with antibodies
30 episodes with antibodies
26 episodes with antibodies
21 episodes with antibodies
11 episodes with antibodies
42 episodes with antibodies
19 episodes with antibodies
11 episodes with antibodies
15 episodes with antibodies
17 episodes with antibodies
8 episodes with antibodies
24 episodes with antibodies
7 episodes with antibodies
12 episodes with antibodies
9 episodes with antibodies
13 episodes with antibodies
6 episodes with antibodies
6 episodes with antibodies
7 episodes with antibodies
23 episodes with antibodies
5 episodes with antibodies
12 episodes with antibodies
7 episodes with antibodies
9 episodes with antibodies
8 episodes with antibodies
9 episodes with antibodies
17 episodes with antibodies
9 episodes with antibodies
6 episodes with antibodies
10 episodes with antibodies
5 episodes with antibodies
7 episodes with antibodies
8 episodes with antibodies
18 episodes with antibodies
10 episodes with antibodies
4 episodes with antibodies
8 episodes with antibodies
5 episodes with antibodies
5 episodes with antibodies
7 episodes with antibodies
7 episodes with antibodies
8 episodes with antibodies
15 episodes with antibodies
6 episodes with antibodies
11 episodes with antibodies
6 episodes with antibodies
“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54
TWiV explains a cohort study of over one million Danish children which shows no evidence supporting an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders associated with early childhood exposure to vaccines with aluminum-base adjuvants, and a study of antibodies induced by mRNA-1273 and NVX-CoV2373 COVID-19 vaccines which show that polyclonal antibodies against a single site on the spike N-terminal domain show immunodominance, high diversity, and limited cross-reactivity, indicating the need to direct antibody responses away from this site. Hosts: Vincent Racaniello, Alan Dove, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV No chronic effects of aluminum-based adjuvants in vaccines (Ann Int Med) Aluminum in vaccines (CHOP) Structural serology of antibody responses to COVID vaccines (Cell Rep) Letters read on TWiV 1239 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – MHC Class I Antigen Presentation Video Alan – We Become What We Behold Vincent – New Injectable Recommended by Europe for HIV Prevention Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with CTSNet Senior Editor Dr. Sameh Said, Chief of the Division of Pediatric and Adult Congenital Cardiac Surgery at Maria Fareri Children's Hospital, Professor of Surgery and Pediatrics at the New York Medical College, and Consultant Cardiac Surgeon at King Faisal Specialist Hospital and Research Center about performing the first successful ex utero intrapartum treatment (EXIT)-to-open atrial septectomy-to-rapid stage I Norwood palliation in a neonate with hypoplastic left heart syndrome and intact interatrial septum. Chapters 00:00 Intro 03:13 JANS 1, Cardiac Transplant 09:04 JANS 2, Lung Transplant 10:19 JANS 3, Cardiac Transplant 11:08 JANS 4, Lung Cancer 13:01 JANS 5, Thoracic 15:44 Video 1, Congenital Cardiac 17:53 Video 2, Cardiac 19:49 Video 3, Cardiac 21:50 Dr. Said Interview, EXIT Procedure 37:28 Upcoming Events 39:32 Closing They discuss the surgical steps involved in this groundbreaking procedure, including specific details about the surgery, the preparation undertaken prior to the operation, and the key factors that contributed to its success. Additionally, they covered the challenges encountered during this first successful EXIT procedure case, as well as the standard management practices for these cases at medical centers, such as fetal balloon atrial septostomy, along with postnatal transcatheter, surgical, or hybrid interventions and their associated surgical risks. Furthermore, they address the broader challenges faced when operating on patients with hypoplastic left heart syndrome, including the differences between restrictive atrial septum and intact atrial septum. Joel also highlights recent JANS articles on the current state and future directions of cardiac xenotransplantation, if age is a contraindication for lung transplantation in the elderly, a summary of the International Society for Heart and Lung Transplantation consensus conference on emerging understanding of antibodies and antibody-mediated rejection in heart transplantation, inflammatory diseases and risk of lung cancer among individuals who have never smoked, and active chest tube clearance added to an Enhanced Recovery After Cardiac Surgery (ERAS) program improves outcomes and reduces resource utilization. In addition, Joel explores a single incision mitral valve repair and LIMA-to-LAD bypass via a left anterior minithoracotomy, repair of post-infarction ventricular septal defect using a double patch sandwich technique, and reconstruction of the left trigone during the Commando procedure for invasive prosthetic aortic valve endocarditis. Before closing, Joel highlights upcoming events in CT surgery. JANS Items Mentioned 1.) Cardiac Xenotransplantation: Current State and Future Directions 2.) Lung Transplantation in the Elderly: Is Age a Contraindication? 3.) Summary of the International Society for Heart and Lung Transplantation Consensus Conference on Emerging Understanding of Antibodies and Antibody-Mediated Rejection in Heart Transplantation 4.) Inflammatory Diseases and Risk of Lung Cancer Among Individuals Who Have Never Smoked 5.) Active Chest Tube Clearance Added to an Enhanced Recovery After Cardiac Surgery (ERAS) Program Improves Outcomes and Reduces Resource Utilization CTSNET Content Mentioned 1.) Single Incision Mitral Valve Repair and LIMA-to-LAD Bypass via a Left Anterior Minithoracotomy 2.) Repair of Post-Infarction Ventricular Septal Defect Using a Double Patch Sandwich Technique 3.) Reconstruction of the Left Trigone During the Commando Procedure for Invasive Prosthetic Aortic Valve Endocarditis Other Items Mentioned 1.) Guest Editor Series: Coronary Arterial Anomalies—Pediatric and Adult Congenital 2.) Cardiac Surgical Arrest—An International Conversation Series 3.) Career Center 4.) CTSNet Events Calendar Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.
Her antibodies were high, her gut was off and surgery was on the table. So she started asking what was really driving her symptoms.Alexandria was told she had the antibodies for both Graves' and Hashimoto's in 2017 and initially followed conventional advice, including methimazole. But after facing the possibility of thyroid removal, she explores deeper root causes. This health audit traces the progress she's made with dietary changes, gut support, and lifestyle shifts and the imminent questions as she prepares for a future pregnancy. We discuss why her antibody levels dropped, where she's still seeing symptoms, and what steps might help her move forward without fully relying on medication.Managing your thyroid but curious about alternative support options? Listen to this episode!Episode Timeline: 00:00 – Episode Overview01:44 – Podcast Intro02:16 – Meet Alexa and her Diagnosis 03:00 – Seeking Alternatives to Thyroid Removal04:42 – Impact of gluten-free and AIP diets06:00 – Goiter changes with diet06:44 – Dairy and food tradeoffs07:14 – Antibody testing history08:03 – Gut support: HCl, Rifaximin, colostrum09:18 – SIBO diagnosis and food sensitivities10:42 – Gluten, permeability, and testing limitations11:33 – Lifelong gut issues and acid blocker use13:23 – Apple cider vinegar and digestive strategies15:19 – Pregnancy while on medication16:00 – Detox planning before conception18:32 – Stool test, travel, and GI infections19:19 – SIBO, food poisoning, and motility damage22:16 – AIP next steps and testing decisions23:52 – Podcast Outro24:13 – Final Thoughts and RecommendationsFree resources for your thyroid healthGet your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.comHigh-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid?Click Here to access hundreds of free articles and blog posts.Click Here for Dr. Eric's YouTube channelClick Here to join Dr. Eric's Graves' disease and Hashimoto's groupClick Here to take the Thyroid Saving Score Quiz Do You Want Help Saving Your Thyroid? Click Here to access hundreds of free articles and blog posts. Click Here for Dr. Eric's YouTube channel Click Here to join Dr. Eric's Graves' disease and Hashimoto's group Click Here to take the Thyroid Saving Score Quiz Click Here to get all of Dr. Eric's published booksClick Here to work with Dr. Eric
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/HAZ865. CME/NCPD/IPCE credit will be available until July 17, 2026.The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/HAZ865. CME/NCPD/IPCE credit will be available until July 17, 2026.The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/HAZ865. CME/NCPD/IPCE credit will be available until July 17, 2026.The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/HAZ865. CME/NCPD/IPCE credit will be available until July 17, 2026.The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/HAZ865. CME/NCPD/IPCE credit will be available until July 17, 2026.The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/HAZ865. CME/NCPD/IPCE credit will be available until July 17, 2026.The BCMA Playbook in Multiple Myeloma: Mastering Sequential Strategies With Bispecific Antibodies and CAR-T Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies
Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies
Laurent Servais, MD, PhD - Eligible for Gene Therapy? The Complexity and Therapeutic Implications of Anti-AAV Antibodies
In this episode, Marc Elia, Chairperson of the Board at Invivyd, discusses his personal experience with COVID-19 and long COVID, the company's unique monoclonal antibody platform, and how Invivyd is working to address persistent gaps in infectious disease prevention and care. He also highlights the importance of patient voices in regulatory processes and the future of scalable, accessible monoclonal antibody therapies.This episode is sponsored by Invivyd.
This podcast episode is designed to offer listeners a discussion about the FDA's evolving stance on animal testing and exploring thoughts on its potential phase-out for monoclonal antibody (mAb) therapies. Hosted by Zac Lloyd and featuring expert insights from Dr. Whitney Helms, Executive Director of Nonclinical Development, Large Molecule Discovery at Eli Lilly and Company, and Dr. Diann Blanset, consultant at Akkeri, Inc., this roundtable-style discussion unpacks the scientific, ethical, and regulatory implications of this paradigm shift. Whether you're deep in the biologics pipeline or navigating the changing CRO landscape, this episode offers valuable perspectives on what the future may hold—and how to prepare for it.
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information and select publications here.
Featuring perspectives from Prof Marina Chiara Garassino, Dr John V Heymach, Prof Solange Peters and Dr Jacob Sands, moderated by Dr Sands, including the following topics: Introduction (0:00) Role of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Prof Peters (2:07) Targeted and Other Novel Therapeutic Strategies for Relapsed Metastatic NSCLC — Prof Garassino (26:30) Potential Role of TROP2-Targeted Antibody-Drug Conjugates in Advanced NSCLC — Dr Sands (50:19) Evolving Role of Immune Checkpoint Inhibitors in the Care of Patients with Nonmetastatic NSCLC — Dr Heymach (1:12:36) CME information and select publications
BUFFALO, NY - July 16, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on July 9, 2025, titled “A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the tumor microenvironment.” In this study, researchers from the National Institute of Allergy and Infectious Diseases, led by first author Maja Buszko and corresponding author Ethan M. Shevach, discovered a new monoclonal antibody that selectively targets a subset of immune cells called regulatory T cells (Tregs). These cells, while normally important for preventing autoimmunity, also can block the body's ability to fight cancer by suppressing anti-tumor immune responses. This discovery could lead to novel cancer therapies that strengthen the immune system's capacity to attack tumors. The researchers identified an anti-CD25 monoclonal antibody with several atypical properties and named it 2B010. To evaluate its effects, they used humanized mice, laboratory mice that are engineered to carry human immune cells, to closely mimic how human immune systems respond to cancer. The treatment of these mouse models with 2B010 significantly decreased the number of Tregs in tumors and boosted the activity of CD8+ T cells, which are essential for killing cancer cells. Importantly, 2B010 worked without disrupting other key immune functions. Unlike traditional Anti-CD25 antibodies, it did not interfere with interleukin-2 (IL-2) signaling, which is essential for the growth and activity of effector T cells that fight cancer. “2B010 also had no effect on IL-2 induced STAT5 phosphorylation or CD4+ T cell proliferation in vitro while both were blocked by Clone D1 further supporting the view that 2B010 does not recognize the IL-2 binding site.” This finding is especially significant because high levels of Tregs in tumors are associated with poor outcomes in many cancers. By specifically removing these cells, 2B010 may help overcome one of the main barriers to current immunotherapy approaches. Its ability to preserve IL-2 signaling could also make it safer and more effective when used alone or in combination with existing therapies such as immune checkpoint inhibitors. While the 2B010 antibody showed strong effects in reducing Tregs and boosting immune cell activity, the study did not observe changes in tumor size in these models. Researchers suggest this may be due to limitations in the preclinical systems used, such as the lack of tumor-specific T cells in humanized mice. Nevertheless, these findings demonstrate that 2B010 has a unique mechanism of action that could complement other cancer immunotherapies in future clinical trials. In conclusion, the development of 2B010 is a promising step toward selectively disrupting the immune suppressive environment in tumors. As researchers continue to refine and test this antibody, it could become a powerful tool for enhancing the effectiveness of cancer treatments and improving outcomes for patients. DOI - https://doi.org/10.18632/oncotarget.28752 Correspondence to - Ethan M. Shevach - eshevach@Niaid.NIH.gov Video short - https://www.youtube.com/watch?v=2NJcGsI7WXA Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28752 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Treg, CD25, TME, mAb, GVHD To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
In this episode of Clinical Lab Chat, CLP Director of Business Intelligence Chris Wolski discusses the critical role diagnostics play in successful organ transplantation with Tina Liedtky, president of Transplant Diagnostics for Thermo Fisher.During the course of the lively conversation, they discuss: How diagnostics fit into the organ transplant process.How diagnostics are helping to up the odds of transplant success both short and long term.The role of post-transplantation diagnostics and how ongoing diagnostic testing helps to keep patients healthy longer.An overview of Thermo Fisher's transplantation diagnostics.What advances we can expect in the next 5 to 10 years.
Could the latest data in novel antibody-drug conjugates reshape your treatment approach for patients with gastric cancer? Credit available for this activity expires: 7/1/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002638?ecd=bdc_podcast_libsyn_mscpedu
Today's episode of the VJHemOnc podcast focuses on the targeting of mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs) – a... The post Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification appeared first on VJHemOnc.
In HIV prevention and treatment, broadly neutralising antibodies have so far failed failed to deliver on their potential; could N6LS buck the trend? Richard Wu talks about a phase 1 study with some promising results.Read the full article:https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00041-4/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanhivContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
TWiV discusses Sen. Cassidy calling for ACIP meeting delay, RFK Jr. abandons GAVI, millions of children at risk as global vaccination rates fall, RFK Jr. grilled by Congress, autism rates have increased 60-fold due to changed definitions, deep mutational scanning of rabies virus glyoprotein, and and proton gradient and incomplete TCA cycle in a giant virus. Hosts: Vincent Racaniello, Rich Condit, Brianne Barker, and Angela Mingarelli Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Sen. Cassidy calls for ACIP delay (NYTimes) RFK Jr. stops GAVI funding (NYTimes) Global vaccination rates drop, millions of children at risk (Guardian) Autism rates have increased 60-fold, here's why (NYTimes) Deep mutational scanning of rabies virus glycoprotein (Cell Host Micr) Giant virus with proton gradient and partial TCA cycle (ISME J) Why cells are powered by proton gradients (Scitable) Timestamps by Jolene Ramsey. Thanks! Weekly Picks Angela – 27 new, exciting, and blobby species discovered in the Peruvian rainforest! Brianne – Encounters in the Milky Way Rich – Where to go for accurate, up-to-date vaccine information Vincent – The members of RFK Jr.'s new vaccine committee have published little on vaccines Listener Picks Charles – Vaccine Advice, Vandalized Ken – Golden Goose Awards Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SDR865. CME credit will be available until May 20, 2026.Adopting Innovation in Bladder Cancer: Aligning the Evidence on Antibody–Drug Conjugates to Inform Treatment Decisions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Astellas and Pfizer, IncDisclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SDR865. CME credit will be available until May 20, 2026.Adopting Innovation in Bladder Cancer: Aligning the Evidence on Antibody–Drug Conjugates to Inform Treatment Decisions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Astellas and Pfizer, IncDisclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SDR865. CME credit will be available until May 20, 2026.Adopting Innovation in Bladder Cancer: Aligning the Evidence on Antibody–Drug Conjugates to Inform Treatment Decisions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Astellas and Pfizer, IncDisclosure information is available at the beginning of the video presentation.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/SDR865. CME credit will be available until May 20, 2026.Adopting Innovation in Bladder Cancer: Aligning the Evidence on Antibody–Drug Conjugates to Inform Treatment Decisions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Astellas and Pfizer, IncDisclosure information is available at the beginning of the video presentation.
In this episode of Hormone & Thyroid Healing with Priscilla Swahn, we explore a healing modality you may have never considered: beauty. Not just skincare or fashion — but the intentional practice of surrounding yourself with what feels beautiful, calming, and nourishing to your feminine nervous system. You'll learn how beauty rituals and aesthetics can lower cortisol, support thyroid function, and gently rewire your relationship with your body. We're flipping the script on healing by asking: what if feeling beautiful is part of the medicine? Whether it's using your favorite china for breakfast, wearing colors that make you glow, or simply decluttering your space to breathe again — this episode is your reminder that healing isn't only about what you remove, but what you welcome in. In this episode, you'll hear: Why women with thyroid or hormone imbalance often feel disconnected from beauty (and how to reclaim it) How beauty-based rituals regulate cortisol and calm the adrenals The science of pleasure and why it matters for thyroid healing Practical, everyday ways to invite beauty into your meals, movement, and mindset The surprising link between aesthetic joy and metabolic resilience A gentle challenge to start your own beauty-as-healing practice this week Let's connect!
Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, like many of its peers, has embraced the trend head-on. In this week’s episode of "The Top Line," Fierce Pharma’s Zoey Becker speaks with Daejin Abidoye, M.D., AbbVie’s vice president and therapeutic area head for solid tumor oncology. They discuss the company’s evolution, trends from this year’s American Society of Clinical Oncology meeting and what’s ahead for ADCs in oncology. AbbVie, a newer player in the ADC space, recently earned FDA approval for Emrelis in adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have previously received systemic therapy. With a robust pipeline of ADCs in development, Abidoye envisions a bright future for the class—one that could herald “a new era” of cancer treatment beyond traditional chemotherapy. To learn more about the topics in this episode: AbbVie advances solid tumor agenda with FDA nod for lung cancer ADC Emrelis AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field Replacing chemotherapy with ADCs? AbbVie rebuilds next-gen assets after Rova-T flop See omnystudio.com/listener for privacy information.
TWiV reviews the administrations dismantling of the committee that studies pandemic potential, firing of CDC vaccine advisory committee and replacing them with unqualified anti-vaxxers, zoonotic and sustained Mpox spread in Nigeria and Cameroon, and breadth of influenza A antibody cross-reactivity. Hosts: Vincent Racaniello, Alan Dove, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV 2:39 NIH terminates pandemic preparedness committee (Science) RFK Jr. fires all ACIP members (CNN) RFK Jr. names dubious members of new ACIP (NPR) Zoonotic and sustained Mpox spread in West Africa (Nature) Breadth of influenza A antibody cross-reactivity (Nat Micro) Letters read on TWiV 1227 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Accidental discovery in planetarium show Alan – Project Hail Mary Vincent – How to speak to a vaccine sceptic: research reveals what works Listener Picks James – Looking at the world through a microscope Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
By Tony Stith - God calls Spirit-led Christians within the body of Christ to serve as spiritual "antibodies"—guarding against the harmful influences and deceptive teachings that threaten the health and unity of His Church. But how can we be sure we're fulfilling this vital role?
Drs. Lipsky and Allan discuss the emerging role of immunotherapy in the management of patients with CLL, including CAR T-cell therapy and bispecific antibodies.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
TWiV reviews the administration's call for fools gold-standard science, NIH may publish in-house, avian influenza viruses in birds in China, and Omicron pathogenicity and immune responses. Hosts: Vincent Racaniello, Alan Dove, Rich Condit, and Kathy Spindler Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Fool's Gold Standard Science (Nature) NIH may publish in-house (Stat News) Diversity of H9N2 in China (Nat Micro) Omicron and immunity (Cell Rep) Letters read on TWiV 1225 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Kathy – mSphere virus species names standardization Rich – Real Tides & Currents Graph HD Alan – Invasive termites spreading from privately owned boats Vincent – Entomologist Answers Insect Questions Listener Picks Gerry – Citations Needed podcast 221: Anti-science mugging Joyrell – Mayday: Air Disaster Favorite one, two, three, for Vincent Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.
Samira, a breast cancer survivor and CEO of Manta Cares, discusses the latest advancements in cancer treatment with Dr. Doug Blayney at the ASCO conference. They explore the significant impact of exercise on cancer treatment tolerance and survival, the de-escalation of chemotherapy, the introduction of new therapies like SERDs and antibody drug conjugates, and the role of circulating tumor DNA in monitoring cancer recurrence. The conversation emphasizes the importance of patient convenience and self-advocacy in cancer care.About Our Guest:Douglas W. Blayney, MD is a Professor of Medicine (Oncology), Emeritus, former Medical Director of Stanford Cancer Center, and specializes in the treatment of breast cancer. He has a special interest in the quality and value of cancer care. Dr. Blayney is a past president of the American Society of Clinical Oncology (ASCO), a founder of the ASCO Quality Symposium, a co-author of the ASCO value framework descriptions, and instigated the ASCO clinical "big data" effort, which is now CancerLinQ. He received the inaugural Ellen Stovall Award for Leadership in Patient Centered Care from the National Coalition for Cancer Survivorship in 2016. He was previously a Professor of Internal Medicine and Medical Director of the Comprehensive Cancer Center at the University of Michigan, and prior to that practiced and led Wilshire Oncology Medical Group, Inc. a physician owned multidisciplinary oncology practice in southern California. He has expertise on clinical trial development, use of oncology drugs in clinical practice, reimbursement and marketing strategies and information technology use.Chapter Codes00:00 The Impact of Exercise on Cancer Treatment02:00 Interview at ASCO Starts06:00 Advancements in Cancer Treatment: De-escalation and AI11:52 Emerging Therapies: SERDs and Antibody Drug Conjugates18:11 Circulating Tumor DNA: A New Frontier in Monitoring24:01 Convenience in Cancer Care: A Patient-Centric ApproachTakeaways- Regular exercise can increase tolerance to cancer treatments.- Data shows exercise has tangible benefits on survival rates.- De-escalation of chemotherapy is a key focus in cancer treatment.- AI is being integrated into cancer treatment guidelines.- Patients can take proactive steps to improve their health.- Oral SIRDs are emerging as a more convenient treatment option.- Antibody drug conjugates target cancer cells with fewer side effects.- Circulating tumor DNA can help detect cancer recurrence earlier.- Convenience in treatment is becoming a priority for patients.- Competition among treatments may help reduce costs for patients.Tags & Keywords:cancer treatment, ASCO, exercise, AI, SIRDs, antibody drug conjugates, circulating tumor DNA, patient care, chemotherapy, cancer survival, health technologyConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @mantacares and visit our website at mantacares.com for more episodes and updates.Listen Elsewhere: Website: https://mantacares.com/pages/podcast?srsltid=AfmBOopEP5GJ-Wd2nL-HYAInrwerIVhyJw67salKT-r9Qb_gadBvbHie YouTube: https://youtu.be/UjsAtpbedA8 Spotify: https://open.spotify.com/episode/7HwhjXHZU0ZWWVkXrCSV7V?si=d5e986f0885a4bbb Apple: https://podcasts.apple.com/us/podcast/cervical-cancer-and-hpv-what-you-need-to-know/id1622669098?i=1000710235401 Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Rafael Fonseca is a distinguished Haematologist at Mayo Clinic, specialising in multiple myeloma and related plasma cell disorders. He earned his medical degree at Universidad Anáhuac in Mexico, and went on to complete his residency in Internal Medicine at the University of Miami, Florida, USA followed by a Hematology and Oncology fellowship at Mayo Clinic in Rochester, Minnesota, USA. Timestamps 01:44 – Quickfire questions 07:25 – CAR-T cell therapy 10:48 – Anti-CD38 antibodies 13:31 – Minimal residual disease 14:30 – Bispecific antibodies 15:31 – Antibody-drug conjugates 19:04 – ASCO 2025 21:24 – Genetic discoveries 26:28 – Fonseca's three wishes
By Tony Stith - In a world growing ever darker and more spiritually diseased, God has given His people a powerful gift: His Holy Spirit. This Pentecost message explores how the Holy Spirit functions not only to strengthen us individually, but also to protect and preserve the spiritual health of the Body of Christ
NBN host Hollay Ghadery speaks with acclaimed poet Rebecca Salazar about their new poetry collection, antibody: poems (McClelland & Stewart, 2025) A powerful follow-up to the Governor General's Literary Award shortlisted sulphurtongue.antibody: poems is a protest, a whisper network, a reclamation of agency, and a ritual for building a survivable world.antibody mobilizes body horror as resistance, refusing to sanitize the atrocities of sexual violence or to silence its survivors. Challenging myths of “perfect” victimhood, this collection honours the messy, rageful, queer, witchy, disabled, and kinky grief work of enduring trauma and learning to want to live. About Rebecca Salazar: Rebecca Salazar (she/they) is a queer, disabled, and racialized Latinx writer currently living on the unceded territory of the Wolastoqiyik people. Their first full-length collection sulphurtongue (McClelland & Stewart) was a finalist for the Governor General's Award for Poetry, the New Brunswick Book Awards, the Atlantic Book Awards, and the League of Canadian Poets' Pat Lowther Memorial Award. antibody is their second poetry collection. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network
Steph talks about identification of gut bacteria that can digest protective mucosal antibodies and Vincent covers a new paper on Zika virus that implicates fetal phagocytes in brain invasion, which may provide insight into the devastating microcephaly outcome of infection during pregnancy. Hosts: Vincent Racaniello, Cindy Leifer, Steph Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Gut bacteria induce mucosal immunodeficiency (Science) Contribution of fetal mononuclear phagocytes to Zika virus neuroinvasion (Cell) TWiV468 discusses Zika and brain slice infection model. Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.
In this episode , Lisa Costa-Bir is joined by leading naturopath, registered nutritionist and educator Rachel Arthur to unpack the complex landscape of autoimmune thyroid disease (AITD). Framing conditions like Hashimoto's and Graves' as systemic immune disorders - not just thyroid dysfunction - Rachel shares powerful clinical insights on diagnosis, treatment, and long-term management. With her trademark clarity and “catch cries” like “kill and spill,” Rachel breaks down the clinical significance of thyroid antibodies Thyroid Peroxidase Antibodies (TPO) and Thyroglobulin Antibodies (TgAb), Thyroid Stimulating Hormone (TSH) as a “whip,” and the self-perpetuating nature of glandular damage. She also dives deep into evidence for antioxidants like glutathione, selenium and, CoQ10, as well as discussing the value of myo-inositol, magnesium, and vitamin D - and whether there is a role for iodine supplementation in AITD. This episode is a must-listen in integrative naturopathic care for AITD - balancing nutrient timing and dose with lifestyle and dietary interventions. Essential listening for practitioners managing immune-thyroid cases in clinic. Covered in this episode: (01:01) Welcome Rachel Arthur (02:14) Autoimmune and thyroid (05:24) Thyroid antibodies (12:30) Antibody levels and severity (16:29) Root causes of elevated antibodies (22:40) Selenium (32:10) Myo-inositol (36:36) Vitamin D (50:55) Iodine (1:02:38) Diets for autoimmunity (1:09:53) Final thoughts Find today's transcript and show notes here: https://www.bioceuticals.com.au/education/podcasts/revolutionary-insights-autoimmune-thyroid-disease Sign up for our monthly newsletter for the latest exclusive clinical tools, articles, and infographics: https://login.bioceuticals.com.au ***DISCLAIMER: The information provided on fx Medicine by BioCeuticals is for educational and informational purposes only. The information provided is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you learn here raises questions or concerns regarding your health.***
In our natural bodies, there are many things inside that keep us alive, although we’ve never seen them. Antibodies, clotting agents, intestinal flora, white blood cells. Now, spiritually speaking, there are invisible forces at work that want to help us and save us, although other forces want to destroy us. Today on A NEW BEGINNING, Pastor Greg Laurie points out the work of God’s Spirit acquaints us with our sin, and acquaints us with our Savior. It’s important we know how to respond. Listen on harvest.org --- Learn more and subscribe to Harvest updates at harvest.org A New Beginning is the daily half-hour program hosted by Greg Laurie, pastor of Harvest Christian Fellowship in Southern California. For over 30 years, Pastor Greg and Harvest Ministries have endeavored to know God and make Him known through media and large-scale evangelism. This podcast is supported by the generosity of our Harvest Partners.Support the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.
In our natural bodies, there are many things inside that keep us alive, although we’ve never seen them. Antibodies, clotting agents, intestinal flora, white blood cells. Now, spiritually speaking, there are invisible forces at work that want to help us and save us, although other forces want to destroy us. Today on A NEW BEGINNING, Pastor Greg Laurie points out the work of God’s Spirit acquaints us with our sin, and acquaints us with our Savior. It’s important we know how to respond. Listen on harvest.org --- Learn more and subscribe to Harvest updates at harvest.org A New Beginning is the daily half-hour program hosted by Greg Laurie, pastor of Harvest Christian Fellowship in Southern California. For over 30 years, Pastor Greg and Harvest Ministries have endeavored to know God and make Him known through media and large-scale evangelism. This podcast is supported by the generosity of our Harvest Partners.Support the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.
Featuring an interview with Dr Jennifer Crombie, including the following topics: Overview of similarities and differences among CD20 x CD3 targeted bispecific antibodies for the treatment of lymphomas (0:00) Optimal integration of CD20 x CD3 bispecific antibodies into treatment algorithms for lymphomas (9:40) Case: A man in his late 60s with relapsed follicular lymphoma (FL) who received mosunetuzumab (23:52) Case: A man in his late 80s with transformed, double-hit diffuse large B-cell lymphoma (DLBCL) who received epcoritamab (28:46) Case: A woman in her early 70s with recurrent FL who received odronextamab on the ELM-1 trial (34:06) Case: A man in his early 80s with multiregimen-relapsed DLBCL who receives glofitamab (43:19) CME information and select publications
Is the “poop pill” a possible treatment for small intestinal bacterial overgrowth (SIBO)? Pro-mask, pro-lockdown, pro-vax words come back to haunt their authors as Covid response critics appointed to key HHS positions; MAHA influencer Dr. Casey Means replaces original Surgeon General nominee; Rating Trump's new vaccine czar, oncologist Vinay Prasad; Is Laetrile effective for cancer? If you're eating a diet rich in fruits and vegetables, do you still need probiotics? Researchers tap an unusual source for antivenom against deadly snakebites—a snake handler who's survived multiple poisonings.
In this episode of the Ducks Unlimited Podcast, we're joined by Dr. RuthAnn Lobos of Purina. We dive deep into puppy health, discussing essential vaccines, building immunity, the science behind proper nutrition, and why it all matters for your duck dog. Plus, Dr. Lobos shares valuable socialization tips to help your puppy grow into a confident hunting companion.Listen now: www.ducks.org/DUPodcastSend feedback: DUPodcast@ducks.org
© 2020-2025 Ivy Podcast Discovery LLC
